Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Fresenius SE KGaA Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Sen

İcra Kurulu Başkanı

€7.0m

Toplam tazminat

CEO maaş yüzdesi	24.0%
CEO görev süresi	3.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Sen'un ücretlendirmesi Fresenius SE KGaA'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€721m
Mar 31 2024	n/a	n/a	€420m
Dec 31 2023	€7m	€2m	€353m
Sep 30 2023	n/a	n/a	€470m
Jun 30 2023	n/a	n/a	€555m
Mar 31 2023	n/a	n/a	€952m
Dec 31 2022	€5m	€1m	€1b
Sep 30 2022	n/a	n/a	€1b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	€2m	€755k	€2b

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 7.74M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.82M ).

Tazminat ve Kazançlar: Michael 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Michael Sen (56 yo)

3.5yrs

Görev süresi

€6,992,000

Tazminat

Mr. Michael Sen is Chairman of the Supervisory Board at Fresenius Medical Care AG from July 14, 2023. He is Chief Executive Officer & President of Fresenius Management SE at Fresenius SE & Co. KGaA since O...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Sen	CEO, President & Chairman of Management Board of Fresenius Management SE	3.5yrs	€6.99m	Veri yok
Sara Hennicken	CFO & Member of the Management Board - Fresenius Management SE	2.1yrs	€2.39m	Veri yok
Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	1.6yrs	€3.12m	Veri yok
Michael Moser	Member of Management Board of Fresenius Management SE	1.3yrs	€1.62m	Veri yok
Robert Moller	Member of the Management Board of Fresenius Management SE	1.1yrs	€1.42m	Veri yok
Markus Georgi	Senior Vice President of Investor Relations	9.5yrs	Veri yok	Veri yok
Matthias Link	Senior Vice President Corporate Communications	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

49.5yo

Ortalama Yaş

Deneyimli Yönetim: 000332902 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerd Krick	Honorary Chairman of Supervisory Board	3.4yrs	€219.00k	Veri yok
Michael Diekmann	Independent Deputy Chairman of the Supervisory Board	9.4yrs	€320.00k	Veri yok
Frank Appel	Member of the Supervisory Board	3.4yrs	€210.00k	Veri yok
Wolfgang Kirsch	Independent Chairman of Supervisory Board	4.8yrs	€560.00k	Veri yok
Grit Genster	Independent Deputy Chairperson of the Supervisory Board	4.4yrs	€310.00k	Veri yok
D. Albrecht	Independent Member of Supervisory Board	13.8yrs	€180.00k	Veri yok
Iris Loew-Friedrich	Independent Member of Supervisory Board	8.4yrs	€180.00k	Veri yok
Susanne Zeidler	Independent Member of the Supervisory Board	3.4yrs	€290.00k	Veri yok
Frauke Lehmann	Independent Member of Supervisory Board	8.4yrs	€180.00k	Veri yok
Oscar De Paco	Independent Member of Supervisory Board	8.4yrs	€180.00k	Veri yok
Bernd Behlert	Independent Member of Supervisory Board	6.1yrs	€215.00k	Veri yok
Christoph Zindel	Independent Member of Supervisory Board	2.4yrs	€220.00k	Veri yok

5.4yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000332902 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Fresenius SE KGaA Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings released: EPS: €0.61 (vs €0.74 in 1Q 2022)

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş